Ravo Vincenzo, Marrone Immacolata, Morra Anna, Manzo Roberto, Murino Paola, Cammarota Fabrizio, Muto Paolo
U.O.C. di Radioterapia Presidio Ospedaliero C. Ascalesi, Napoli, Italy.
Dipartimento Assistenziale di Radiologia e Radioterapia - Seconda Università degli Studi di Napoli, Italy.
Rep Pract Oncol Radiother. 2010 Oct 6;15(5):119-24. doi: 10.1016/j.rpor.2010.08.006. eCollection 2010.
Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment of locally advanced soft tissues sarcomas of the extremities. Moreover the employment of combined modalities in locally advanced soft tissues sarcomas of the extremities allow to maximize the chance of local cure even in difficult presentation cases, and possibly improve survival, especially in high-risk disease patients. In patients with sarcomas of the extremities in which definitive surgery has not been radical (with positive or "close" margins) radiotherapy can improve the results in terms of Disease Free Survival (DFS) and, together with chemotherapy, of Overall Survival (OS). We recommend radiotherapy in case of deep tumor location, inadequate surgical margins and grade 3 tumour; for positive or "marginal (or close)" excision (that means inadequate surgery) or in selected patients with a bad prognosis, we believe that a multidisciplinary approach can be preferable.
Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment. In patients with sarcomas of the extremities in whom definitive surgery has been or not radical (positive or "close" margins), radiotherapy with chemotherapy can improve the results in terms of Disease Free Survival (DFS) and Overall Survival (OS), while RTE alone seems to improve local control.
From 1/2000 to 12/2005 we treated 34 patients affected by locally advanced sarcomas of the upper or lower extremities with radiotherapy (doses ranging from 54 to 66 Gy) and chemotherapy in 18/34 with an adjuvant scheme that consisted in Epirubicine (120 mg/m(2)) plus Ifosfamide (7000-9000 mg/m(2)).
Disease Free Survival (DFS) and the Overall Survival (OS) rates were 76% and 82%, respectively. Eighteen patients developed one or more long-term side effects. Most of these complications were mild: all patients experienced only erithema, edema, local sclerosis or moderate pain.
Radiotherapy has an important role as a post-operative treatment also when surgery was non-radical. It improves local control more in patients with high-grade sarcomas of the extremity with positive or close margins. It is still difficult to assess the role of adjuvant chemotherapy.
辅助放疗(RTE)作为肢体局部晚期软组织肉瘤的术后治疗仍具有重要作用。此外,在肢体局部晚期软组织肉瘤中采用联合治疗方式,即使在病情复杂的情况下,也能最大程度地提高局部治愈的机会,并有可能提高生存率,尤其是在高危疾病患者中。对于肢体肉瘤患者,如果根治性手术未达到根治效果(切缘阳性或“接近”切缘),放疗可在无病生存期(DFS)方面改善治疗效果,并且与化疗一起可改善总生存期(OS)。对于肿瘤位置深、手术切缘不充分和3级肿瘤的情况,我们建议进行放疗;对于切缘阳性或“边缘(或接近)”切除(即手术不充分)的情况或在某些预后不良的患者中,我们认为多学科方法可能更可取。
辅助放疗(RTE)作为术后治疗仍具有重要作用。对于肢体肉瘤患者,无论根治性手术是否达到根治效果(切缘阳性或“接近”切缘),放疗联合化疗可在无病生存期(DFS)和总生存期(OS)方面改善治疗效果,而单纯辅助放疗似乎可改善局部控制。
从2000年1月至2005年12月,我们对34例上肢或下肢局部晚期肉瘤患者进行了放疗(剂量范围为54至66 Gy),其中18例联合化疗,辅助化疗方案为表柔比星(120 mg/m²)加异环磷酰胺(7000 - 9000 mg/m²)。
无病生存期(DFS)和总生存期(OS)率分别为76%和82%。18例患者出现一种或多种长期副作用。这些并发症大多较轻:所有患者仅出现红斑、水肿、局部硬化或中度疼痛。
即使手术不彻底,放疗作为术后治疗也具有重要作用。对于切缘阳性或接近切缘的肢体高级别肉瘤患者,放疗能更好地改善局部控制。辅助化疗的作用仍难以评估。